Henry Schein Reaches New 52-Week High (HSIC)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Henry Schein (Nasdaq: HSIC) hit a new 52-week high Thursday as it is currently trading at $97.21, above its previous 52-week high of $97.15 with 186,660 shares traded as of 2:40 p.m. ET. Average volume has been 359,100 shares over the past 30 days.

Henry Schein has a market cap of $8.41 billion and is part of the services sector and wholesale industry. Shares are up 20% year to date as of the close of trading on Wednesday.

Henry Schein, Inc. distributes health care products and services primarily to office-based dental, medical, and animal health care practitioners. It operates in two segments, Health Care Distribution and Technology and Value-Added Services. The company has a P/E ratio of 21.6, above the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Henry Schein as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, notable return on equity and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. You can view the full Henry Schein Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Henry Schein: Cramer's Top Takeaways

Stocks Are Fighting Back: Cramer's 'Mad Money' Recap (Wednesday 8/9/17)

Analysts' Actions -- Lululemon, L Brands, Masco, Under Armour and More

End of Health-Care Bill Could Be a Win for Markets: Cramer's 'Mad Money' Recap (Friday 3/24/17)

Walmart, Nike, Henry Schein Set to Shine